Lek Pharmaceuticals D.D.
Records under this name other than the patents Lek Pharmaceuticals D.D. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 15 patents it holds.
Back to Lek Pharmaceuticals D.D.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,874,618 | Compositions for Treatment of Heart Failure in Dogs Formerly held In force · High confidence | In force | High confidence | |
| US 11,851,666 | Multi-Copy Gene Protein Expression System Formerly held In force · High confidence | In force | High confidence | |
| US 8,785,674 | Process for Hydrogenation of Halogenoalkenes Without Dehalogenation Lapsed on the fee record Ended Jul 22, 2026 · Medium confidence | Lapsed on the fee record | Ended Jul 22, 2026 | Medium confidence |
| US 8,728,816 | Production of Glycoproteins with Low N-Glycolylneuraminic Acid (NEU5GC) Content Lapsed on the fee record Ended May 20, 2026 · High confidence | Lapsed on the fee record | Ended May 20, 2026 | High confidence |
| US 8,592,474 | Process for the preparation or purification of olmesartan medoxomil Lapsed on the fee record Ended Nov 26, 2025 · From the USPTO record | Lapsed on the fee record | Ended Nov 26, 2025 | From the USPTO record |
| US 9,732,053 | 1-[2-(2,4-dimethylphenylsulfanyl) phenyl]piperazine acetate in crystalline form Lapsed on the fee record Ended Aug 15, 2025 · From the USPTO record | Lapsed on the fee record | Ended Aug 15, 2025 | From the USPTO record |
| US 8,471,045 | Synthesis of statins Lapsed on the fee record Ended Jun 25, 2025 · From the USPTO record | Lapsed on the fee record | Ended Jun 25, 2025 | From the USPTO record |
| US 8,404,870 | ((2S,4R)-4,6-dihydroxytetrahydro-2H-pyran-2-yl)methyl carboxylate and process for the production thereof Lapsed on the fee record Ended Mar 26, 2025 · From the USPTO record | Lapsed on the fee record | Ended Mar 26, 2025 | From the USPTO record |
| US 8,354,530 | Process for the synthesis of rosuvastatin calcium Lapsed on the fee record Ended Jan 15, 2025 · From the USPTO record | Lapsed on the fee record | Ended Jan 15, 2025 | From the USPTO record |
| US 9,512,097 | Process for the preparation of 3-aroyl-5-aminobenzofuran derivatives Lapsed on the fee record Ended Dec 6, 2024 · From the USPTO record | Lapsed on the fee record | Ended Dec 6, 2024 | From the USPTO record |